FTC breast enhancement case
This article was originally published in The Rose Sheet
Executive Summary
J. Michael Ernest, PhD, Isis Breast Enhancement System developer, agrees to settle FTC charges he made deceptive statements in print, radio, TV, Internet ads for the supplement/topical cream combo, commission says Jan. 22. Proposed stipulated final order requires Ernest to "have competent and reliable scientific evidence" before making any claims about Isis, other products. Settlement follows recent case brought by FTC against Isis marketer Vital Dynamics, which was settled in December (1"The Rose Sheet" Jan. 6, 2003, p. 11)...
You may also be interested in...
Isis Breast Enhancement System Safety, Efficacy Questioned By FTC
Vital Dynamics promoted its Isis Breast Enhancement System as free of side effects after receiving "hundreds of reports of negative side effects," according to a Federal Trade Commission complaint
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.